Potential of Cannabis, Cannabinoid Products in Managing Cancer Symptom Burden
Researchers conducted a literature search for evidence of the effects of medical marijuana products on symptom burden in patients with cancer.
Researchers conducted a literature search for evidence of the effects of medical marijuana products on symptom burden in patients with cancer.
Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.
Results of a study comparing weight loss success of a diet and physical activity intervention with self-directed weight loss among ALL survivors are presented at 2021 ASCO Annual Meeting.
A cost analysis shows daratumumab may be better used as a second-line treatment for transplant-ineligible patients with multiple myeloma.
Commonly reported AEs of selinexor include nausea, anorexia, fatigue, thrombocytopenia, and hyponatremia.
Structured palliative care can ensure these patients and their caregivers have an optimal experience that does not hinder trial outcomes.
Using remote communications technology, a major cancer center was able to manage symptoms in high-risk patients initiating treatment at a regional location.
Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
Researchers surveyed consecutive new patients at a multidisciplinary clinic to determine smokers’ willingness to participate in a cessation program.
A single-item visual analog scale has been shown to ensure that oncologists’ perceptions and patients’ wishes for end of life care are in agreement.